Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study

Journal of Clinical Oncology

Volumn 35, Issue 22, 2017, Pages 2535-2541

  Ott, Patrick A ^a   Bang, Yung Jue ^g   Berton Rigaud, Dominique ^h   Elez, Elena ^j   Pishvaian, Michael J ^b   Rugo, Hope S ^c   Puzanov, Igor ^d   Mehnert, Janice M ^e   Aung, Kyaw L ^k   Lopez, Juanita ^l   Carrigan, Marion ^f   Saraf, Sanatan ^f   Chen, Mei ^f   Soria, Jean Charles ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Seoul National University College of Medicine   (South Korea)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARCINOSARCOMA; CHILL; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ANOREXIA; CARCINOMA; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; RETREATMENT; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FATIGUE; FEMALE; FEVER; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; SURVIVAL RATE;

EID: 85026732536     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.72.5952     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
2. Colombo N, Preti E, Landoni F, et al: Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24: vi33-vi38, 2013 (suppl 6)
3. Wright JD, Barrena Medel NI, Sehouli J, et al: Contemporary management of endometrial cancer. Lancet 379:1352-1360, 2012
4. Dowdy SC: Improving oncologic outcomes for women with endometrial cancer: Realigning our sights. Gynecol Oncol 133:370-374, 2014
5. National Comprehensive Cancer Network: Clinical Practice Guidelines for Uterine Neoplasms, 2016. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
6. Moxley KM, McMeekin DS: Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents. Oncologist 15: 1026-1033, 2010
7. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
8. Longoria TC, Eskander RN: Immunotherapy in endometrial cancer: An evolving therapeutic paradigm. Gynecol Oncol Res Pract 2:11, 2015
9. Erratum Longoria TC, Eskander RN: Immunotherapy in endometrial cancer: An evolving therapeutic paradigm. Gynecol Oncol Res Pract 3:2, 2016
10. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297, 2002
11. Spranger S, Spaapen RM, Zha Y, et al: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5:200ra116, 2013
12. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
13. Sharma P, Allison JP: The future of immune checkpoint therapy. Science 348:56-61, 2015
14. Vanderstraeten A, Luyten C, Verbist G, et al: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. Cancer Immunol Immunother 63:545-557, 2014
15. Keytruda package insert. Whitehouse Station, NJ, Merck Sharp & Dohme, 2017
16. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028, 2015
17. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
18. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
19. Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:1823-1833, 2016
20. Dolled-Filhart M, Roach C, Toland G, et al: Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 140:1243-1249, 2016
21. Mehnert JM, Panda A, Zhong H, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 126: 2334-2340, 2016
22. Khoja L, Butler MO, Kang SP, et al: Pembrolizumab. J Immunother Cancer 3:36, 2015
23. Bestvina CM, Fleming GF: Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist 21:1250-1259, 2016
24. Bregar A, Robison K, Dizon DS: Update on the chemotherapeutic management of endometrial cancer. Clin Adv Hematol Oncol 12:659-665, 2014
25. Aghajanian C, Sill MW, Darcy KM, et al: Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 29:2259-2265, 2011
26. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014
27. Van Allen EM, Miao D, Schilling B, et al: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207-211, 2015
28. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015
29. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015
30. Kandoth C, Schultz N, Cherniack AD, et al: Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73, 2013
31. Ribas A, Robert C, Hodi S, et al: Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 33, 2015 (suppl; abstr 3001)
32. Seiwert TY, Burtness B, Weiss J, et al: Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. J Clin Oncol 33, 2015 (suppl; abstr 6017)
33. Shankaran V, Muro K, Bang YJ, et al: Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). J Clin Oncol 33, 2015 (suppl; abstr 3026)